Felipe Francisco Tuon1,2, Jaime L Rocha3, Marcelo R Formigoni-Pinto4. 1. Department of Medicine, School of Health and Biosciences, Pontifícia Universidade Católica do Paraná, Curitiba, PR, Brazil. tuon@ufpr.br. 2. Hospital de Clínicas-Serviço de Infectologia, 3º. andar, Rua General Carneiro, 180-Alto da Glória, Curitiba, PR, 80060-900, Brazil. tuon@ufpr.br. 3. Department of Medicine, School of Health and Biosciences, Pontifícia Universidade Católica do Paraná, Curitiba, PR, Brazil. 4. Scientific Medical Division, AstraZeneca, São Paulo, SP, Brazil.
Abstract
PURPOSE: Ceftazidime-avibactam is an antimicrobial association active against several Enterobacteriaceae species, including those resistant to carbapenem. Considering the importance of this drug in the current panorama of multidrug-resistant bacteria, we performed a systematic review about ceftazidime-avibactam with emphasis on clinical and pharmacological published data. METHODS: A systematic search of the medical literature was performed. The databases searched included MEDLINE, EMBASE and Web of Science (until September 2017). The search terms used were 'avibactam', 'NXL104' and 'AVE1330A'. Bibliographies from those studies were also reviewed. Ceftazidime was not included as a search term, once relevant studies about avibactam in association with other drugs could be excluded. Only articles in English were selected. No statistical analysis or quality validation was included in this review. RESULTS: A total of 151 manuscripts were included. Ceftazidime-avibactam has limited action against anaerobic bacteria. Avibactam is a potent inhibitor of class A, class C, and some class D enzymes, which includes KPC-2. The best pharmacodynamic profile of ceftazidime-avibactam is ƒT > MIC, validated in an animal model of soft tissue infection. Three clinical trials showed the efficacy of ceftazidime-avibactam in patients with intra-abdominal and urinary infections. Ceftazidime-avibactam has been evaluated versus meropenem/doripenem in hospitalized adults with nosocomial pneumonia, neutropenic patients and pediatric patients. CONCLUSION: Ceftazidime-avibactam has a favorable pharmacokinetic profile for severe infections and highly active against carbapenemases of KPC-2 type.
PURPOSE:Ceftazidime-avibactam is an antimicrobial association active against several Enterobacteriaceae species, including those resistant to carbapenem. Considering the importance of this drug in the current panorama of multidrug-resistant bacteria, we performed a systematic review about ceftazidime-avibactam with emphasis on clinical and pharmacological published data. METHODS: A systematic search of the medical literature was performed. The databases searched included MEDLINE, EMBASE and Web of Science (until September 2017). The search terms used were 'avibactam', 'NXL104' and 'AVE1330A'. Bibliographies from those studies were also reviewed. Ceftazidime was not included as a search term, once relevant studies about avibactam in association with other drugs could be excluded. Only articles in English were selected. No statistical analysis or quality validation was included in this review. RESULTS: A total of 151 manuscripts were included. Ceftazidime-avibactam has limited action against anaerobic bacteria. Avibactam is a potent inhibitor of class A, class C, and some class D enzymes, which includes KPC-2. The best pharmacodynamic profile of ceftazidime-avibactam is ƒT > MIC, validated in an animal model of soft tissue infection. Three clinical trials showed the efficacy of ceftazidime-avibactam in patients with intra-abdominal and urinary infections. Ceftazidime-avibactam has been evaluated versus meropenem/doripenem in hospitalized adults with nosocomial pneumonia, neutropenicpatients and pediatric patients. CONCLUSION:Ceftazidime-avibactam has a favorable pharmacokinetic profile for severe infections and highly active against carbapenemases of KPC-2 type.
Authors: Marisa L Winkler; Krisztina M Papp-Wallace; Magdalena A Taracila; Robert A Bonomo Journal: Antimicrob Agents Chemother Date: 2015-02-17 Impact factor: 5.191
Authors: Elizabeth Temkin; Julian Torre-Cisneros; Bojana Beovic; Natividad Benito; Maddalena Giannella; Raúl Gilarranz; Cameron Jeremiah; Belén Loeches; Isabel Machuca; María José Jiménez-Martín; José Antonio Martínez; Marta Mora-Rillo; Enrique Navas; Michael Osthoff; Juan Carlos Pozo; Juan Carlos Ramos Ramos; Marina Rodriguez; Miguel Sánchez-García; Pierluigi Viale; Michel Wolff; Yehuda Carmeli Journal: Antimicrob Agents Chemother Date: 2017-01-24 Impact factor: 5.191
Authors: Johanna Berkhout; Maria J Melchers; Anita C van Mil; Wright W Nichols; Johan W Mouton Journal: Antimicrob Agents Chemother Date: 2014-12-08 Impact factor: 5.191
Authors: Jared L Crandon; Virna J Schuck; Mary Anne Banevicius; Marie-Eve Beaudoin; Wright W Nichols; M Angela Tanudra; David P Nicolau Journal: Antimicrob Agents Chemother Date: 2012-09-17 Impact factor: 5.191
Authors: E Osano; Y Arakawa; R Wacharotayankun; M Ohta; T Horii; H Ito; F Yoshimura; N Kato Journal: Antimicrob Agents Chemother Date: 1994-01 Impact factor: 5.191
Authors: Johanna Berkhout; Maria J Melchers; Anita C van Mil; Seyedmojtaba Seyedmousavi; Claudia M Lagarde; Virna J Schuck; Wright W Nichols; Johan W Mouton Journal: Antimicrob Agents Chemother Date: 2015-11-02 Impact factor: 5.191
Authors: Catherine L Tooke; Philip Hinchliffe; Eilis C Bragginton; Charlotte K Colenso; Viivi H A Hirvonen; Yuiko Takebayashi; James Spencer Journal: J Mol Biol Date: 2019-04-05 Impact factor: 5.469
Authors: Pan Gao; Zonglai Liu; Han Yang; Ziqiu He; Zhi Zhang; Xiong Guo; Hongbo Zhang; Wei Ai; Dan Du Journal: J Int Med Res Date: 2020-04 Impact factor: 1.671